Gregory J. Divis net worth and biography

Gregory Divis Biography and Net Worth

Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of our Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles within the company, including Chief Operating Officer, Executive Vice President, and Chief Commercial Officer. Greg brings over 25 years of experience in building and leading business and financial operations within the pharmaceutical industry. Prior to joining Avadel, Greg served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. He also served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women's health. Prior to Lumara, Greg held general management, sales, marketing, and business development roles at Schering-Plough, which was acquired by Merck & Co., Inc., and Sanofi-Aventis. Greg earned his bachelor's degree from the University of Iowa.

What is Gregory J. Divis' net worth?: The estimated net worth of Gregory J. Divis is at least $92,900.00 as of December 9th, 2024. Mr. Divis owns 10,000 shares of Avadel Pharmaceuticals stock worth more than $92,900 as of May 8th. This net worth evaluation does not reflect any other assets that Mr. Divis may own. Additionally, Mr. Divis receives an annual salary of $985,200.00 as CEO at Avadel Pharmaceuticals. Learn More about Gregory J. Divis' net worth.
How old is Gregory J. Divis?: Mr. Divis is currently 57 years old. There are 5 older executives and no younger executives at Avadel Pharmaceuticals. Learn More on Gregory J. Divis' age.
What is Gregory J. Divis' salary?: As the CEO of Avadel Pharmaceuticals plc, Mr. Divis earns $985,200.00 per year. Learn More on Gregory J. Divis' salary.
How do I contact Gregory J. Divis?: The corporate mailing address for Mr. Divis and other Avadel Pharmaceuticals executives is 10 EARLSFORT TERRACE, DUBLIN L2, D02. Avadel Pharmaceuticals can also be reached via phone at (531) 901-5201 and via email at investors@avadel.com. Learn More on Gregory J. Divis' contact information.
Has Gregory J. Divis been buying or selling shares of Avadel Pharmaceuticals?: Gregory J. Divis has not been actively trading shares of Avadel Pharmaceuticals in the last ninety days. Most recently, on Monday, December 9th, Gregory J. Divis bought 402 shares of Avadel Pharmaceuticals stock. The stock was acquired at an average cost of $9.82 per share, with a total value of $3,947.64. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $98,200. Learn More on Gregory J. Divis' trading history.
Who are Avadel Pharmaceuticals' active insiders?: Avadel Pharmaceuticals' insider roster includes Gregory Divis (CEO), Geoffrey Glass (Director), Geoffrey Glass (Director), Thomas McHugh (CFO), Linda Palczuk (Director), and Peter Thornton (Director). Learn More on Avadel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Avadel Pharmaceuticals?: During the last twelve months, Avadel Pharmaceuticals insiders bought shares 8 times. They purchased a total of 55,579 shares worth more than $526,363.04. The most recent insider tranaction occured on January, 21st when Director Linda Palczuk bought 5,000 shares worth more than $39,650.00. Insiders at Avadel Pharmaceuticals own 4.8% of the company. Learn More about insider trades at Avadel Pharmaceuticals.
Information on this page was last updated on 1/21/2025.

Gregory J. Divis Insider Trading History at Avadel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Buy	402	$9.82	$3,947.64	10,000
12/6/2024	Buy	9,598	$9.98	$95,788.04	9,598
8/10/2023	Buy	10,000	$13.20	$132,000.00	159,100
8/12/2020	Buy	13,000	$7.78	$101,140.00

Gregory J. Divis Buying and Selling Activity at Avadel Pharmaceuticals

Avadel Pharmaceuticals Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Today's Range

Now: $9.29

$8.98

$9.77

50 Day Range

MA: $8.04

$6.59

$9.47

2 Week Range

Now: $9.29

$6.38

$17.85

Volume

521,979 shs

Average Volume

1,238,770 shs

Market Capitalization

$897.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Gregory Divis Biography and Net Worth

What is Gregory J. Divis' net worth?

How old is Gregory J. Divis?

What is Gregory J. Divis' salary?

How do I contact Gregory J. Divis?

Has Gregory J. Divis been buying or selling shares of Avadel Pharmaceuticals?

Who are Avadel Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Avadel Pharmaceuticals?